Bispecific T Cell Engager

Cullinan Therapeutics will present preclinical data on CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025. Studies show CLN-978 rapidly depleted B cells in samples from RA, Sjögren’s, and SLE patients, and in nonhuman primates after subcutaneous dosing. In a SLE mouse model, it reduced B cells, anti-dsDNA IgG, and kidney IgG deposition. Cullinan is advancing CLN-978 in OUTRACE clinical programs for RA, SjD, and SLE.